09:46 AM EST, 01/14/2025 (MT Newswires) -- Eterna Therapeutics' ( ERNA ) shares nearly doubled in early trading on Tuesday after the company reported positive results from a preclinical study of its lead cell therapy product ERNA-101

Eterna said the proof-of-concept study demonstrated "massive" T cell infiltration after only one dose, with reduced tumor burden and extended survival in mice with ovarian cancer.

By changing the tumor microenvironment from having low immune activity to an active immune environment, ERNA-101 "may not only lead to improved therapeutic outcomes as a monotherapy but is also anticipated to significantly enhance the efficacy of CAR-T and CAR-NK cell therapies in the future," the company said.

Regarding safety, body weight distribution showed no significant difference between the ERNA-101 and control groups, Eterna said.

Price: 0.4959, Change: +0.19, Percent Change: +60.49